G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Doxorubicin-induced congestive heart failure in adults.
Mohamed M. Haq,Sewa S. Legha,Janak Choksi,Gabriel N. Hortobagyi,Robert S. Benjamin,Michael S. Ewer,M. K. Ali +6 more
TL;DR: It is concluded that in a majority of patients, doxorubicin‐induced congestive heart failure is easily treatable and frequently controlled with digitalis and diuretics.
Journal ArticleDOI
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer
TL;DR: It is possible that an intrinsic, rather than acquired, drug resistance may play a role in the failure of induction chemotherapy for locally advanced breast cancer.
Journal ArticleDOI
Factors associated with participation in breast cancer treatment clinical trials.
TL;DR: In this paper, the authors report on factors related to CT participation among women who were invited to participate in a CT for breast cancer, and find that the factors best explaining participation were trial phase, perceived drawbacks, time and trav...
Journal ArticleDOI
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.
Ian J. Bristol,Wendy A. Woodward,Eric A. Strom,Massimo Cristofanilli,D. Domain,S. Eva Singletary,George H. Perkins,Julia L. Oh,Tse Kuan Yu,Welela Terrefe,Aysegul A. Sahin,Kelly K. Hunt,Gabriel N. Hortobagyi,Thomas A. Buchholz +13 more
TL;DR: Escalation of postmastectomy radiation dose to 66 Gy appears to benefit patients with disease that responds poorly to chemotherapy, those with positive, close, or unknown margin status, and those <45 years of age.
Journal ArticleDOI
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
Eugene H. Huang,Susan L. Tucker,Eric A. Strom,Marsha D. McNeese,Henry Mark Kuerer,Gabriel N. Hortobagyi,Aman U. Buzdar,Vicente Valero,George H. Perkins,Naomi R. Schechter,Kelly K. Hunt,Aysegul A. Sahin,Thomas A. Buchholz +12 more
TL;DR: Although the long-term rate of L RR after neoadjuvant chemotherapy, mastectomy, and radiotherapy is low, a number of factors that correlated independently with greater rates of LRR are identified.